Regeneron Reports Third Quarter 2021 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Regeneron's (REGN) Antibody Cocktail Can Prevent Covid-19 Infection for 8 Months, Phase 3 Data Shows
November 8, 2021 8:30 AM ESTShares of Regeneron Pharmaceuticals (NASDAQ: REGN) are up 1.5% in pre-open Monday after the company announced new phase 3 trial results for its antibody cocktail against COVID-19 infections.
Data showed that risks of getting COVID-19 were slashed by 82% for up to eight months in patients that... More
Regeneron (REGN) Tops Q3 EPS by $6.15
November 4, 2021 6:37 AM EDTRegeneron (NASDAQ: REGN) reported Q3 EPS of $15.37, $6.15 better than the analyst estimate of $9.22. Revenue for the quarter came in at $3.45 billion versus the consensus estimate of $2.76 billion.
For earnings history and earnings-related data on Regeneron (REGN) click here.
... More